Renhuang Pharmaceuticals, Inc. (“Renhuang” or the “Company”, stock symbol: RHGP.OB), a leading Chinese integrated drug developer, manufacturer and distributor, today announced the successful laboratory production of lyophilized syringin powder, its new powder injection anti-depression and fatigue drug. Renhuang expects this new drug to become its next revenue growth driver. At 90% purity, the syringin portion in the sample drugs meets the criteria of the State Food and Drug Administration (SFDA). Renhuang is expected to soon start clinical trials to evaluate both the efficacy and the safety of this new drug for depression and fatigue patients.

Lyophilized syringin powder for injection is developed independently by Renhuang as a new form of pure Chinese herbal medicine that does not have any of the side-effects of other synthetic anti-depression drugs commonly used by patients around the world. Renhuang is in the process to file an invention patent application for this new drug with the State Intellectual Property Office of the P.R.C (SIPO). The product is expected to be classified as a “Class One” new drug by SFDA representing a major breakthrough in anti-depression drug development worldwide. This new drug can also be used as anti-exhaustion treatment, wound stancher and healthy gland growth nutrition.